Abstract
Pirtobrutinib (Jaypirca(TM)), a highly selective, non-covalent, reversible Bruton's tyrosine kinase (BTK) inhibitor, is being developed by Eli Lilly a......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
